Antibiotice SA
Antibiotice's EU Taxonomy Data Preview
In 2024, Antibiotice was subject to the Corporate Sustainability Reporting Directive (CSRD)'s requirements, which mandated the company to publish EU Taxonomy disclosures.
The company reported the eligibility and alignment of Turnover, Capital Expenditure (CAPEX) and Operating Expenditure (OPEX) with the EU Taxonomy, helping assess the extent to which its business activities align with Europe's environmental sustainability goals.
Antibiotice has also provided an activity-level breakdown of its EU Taxonomy disclosures. This granular reporting enhances transparency around which economic activities of Antibiotice are considered environmentally sustainable and contribute to at least one of the six environmental objectives defined under the EU Taxonomy framework.
| Metric (tonnes) | 2024 | 2023 | 2022 | 2021 - 2017 |
|---|---|---|---|---|
Total Taxonomy Aligned A1 Turnover | Copy restricted. Please purchase to unlock this data.  | Copy restricted. Please purchase to unlock this data. | Copy restricted. Please purchase to unlock this data. | 0000000 |
Total Taxonomy Eligible A Turnover | Copy restricted. Please purchase to unlock this data.  a | Copy restricted. Please purchase to unlock this data. | Copy restricted. Please purchase to unlock this data. | 0000000 |
Total Taxonomy Non-Eligible B Turnover | Copy restricted. Please purchase to unlock this data.  a | Copy restricted. Please purchase to unlock this data.  b | Copy restricted. Please purchase to unlock this data. c | 0000000 |
| Metric (tonnes) | 2024 | 2023 | 2022 | 2021 - 2017 |
|---|---|---|---|---|
Total Taxonomy Aligned A1 Opex | Copy restricted. Please purchase to unlock this data. | Copy restricted. Please purchase to unlock this data.  b | Copy restricted. Please purchase to unlock this data.  c | 0000000 |
Total Taxonomy Eligible A Opex | Copy restricted. Please purchase to unlock this data.  a | Copy restricted. Please purchase to unlock this data. b | Copy restricted. Please purchase to unlock this data. c | 0000000 |
Total Taxonomy Non-Eligible B Opex | Copy restricted. Please purchase to unlock this data.  a | Copy restricted. Please purchase to unlock this data.  b | Copy restricted. Please purchase to unlock this data.  c | 0000000 |
c
c
c
c
c
c| Metric (tonnes) | 2024 | 2023 | 2022 | 2021 - 2017 |
|---|---|---|---|---|
Total Taxonomy Aligned A1 Capex | Copy restricted. Please purchase to unlock this data. | Copy restricted. Please purchase to unlock this data.  b | Copy restricted. Please purchase to unlock this data.  c | 0000000 |
Total Taxonomy Eligible A Capex | Copy restricted. Please purchase to unlock this data.  a | Copy restricted. Please purchase to unlock this data. b | Copy restricted. Please purchase to unlock this data. c | 0000000 |
Total Taxonomy Non-Eligible B Capex | Copy restricted. Please purchase to unlock this data.  a | Copy restricted. Please purchase to unlock this data.  b | Copy restricted. Please purchase to unlock this data.  c | 0000000 |
b
b
c
c
b
b
cVerified Sources Behind Antibiotice’s EU Taxonomy Data
Every figure on this dashboard has a transparent audit trail. With Tracenable, each data point is traceable back to its original source, viewable directly inside our platform. Explore Antibiotice’s data sources below and access millions more through our Disclosure Search.
Insights into Antibiotice's Revenues from Sustainable Activities
In 2024, Antibiotice reported EU Taxonomy-eligible revenues of RON 530.87 million, representing 78.65% of its total turnover. Of this amount, RON 0 of Antibiotice's revenues was classified as EU Taxonomy-aligned, indicating that 0% of the revenue-generating activities undertaken by the company substantially contribute to one or more of the six environmental objectives, meet the Do No Significant Harm (DNSH) criteria, and comply with the Minimum Social Safeguards (MSS). a
Insights into Antibiotice's CAPEX from Sustainable Activities
In 2024, Antibiotice reported EU Taxonomy-eligible CAPEX of RON 85.77 million, representing 73.84% of its total CAPEX. Of this amount, RON 0 of Antibiotice's CAPEX was classified as EU Taxonomy-aligned, indicating that 0% of the company's investments were directed toward economic activities that substantially contribute to one or more of the six environmental objectives, meet the Do No Significant Harm (DNSH) criteria, and comply with the Minimum Social Safeguards (MSS). a
Antibiotice's Taxonomy-Eligible Capex Over Time
- Total Taxonomy Aligned A1 Capex
- Total Taxonomy Eligible but Not Aligned A2 Capex
Have Antibiotice's increased its investment in sustainable activities over time?
Since 2022, Antibiotice's taxonomy-aligned capital expenditure (CAPEX) decreased by 100%, indicating a long-term decline in green capital deployment, potentially signaling shifting priorities or reduced focus on sustainability-linked investments. a c
Compared to the previous year (2023), Antibiotice's taxonomy-aligned CAPEX decreased by 100%, suggesting that Antibiotice may have scaled back investments in sustainable projects, reprioritized its capital deployment, or reduced transparency in its taxonomy-aligned disclosures. a b
Insights into Antibiotice's OPEX from Sustainable Activities
In 2024, Antibiotice reported EU Taxonomy-eligible OPEX of RON 6.06 million, representing 12.29% of its total operating expenses (OPEX). Of this amount, RON 0 of Antibiotice's OPEX was classified as EU Taxonomy-aligned, indicating that 0% of the company's operating expenses were directed toward economic activities that substantially contribute to one or more of the six environmental objectives, meet the Do No Significant Harm (DNSH) criteria, and comply with the Minimum Social Safeguards (MSS). a
Antibiotice's Taxonomy-Eligible Opex Over Time
- Total Taxonomy Aligned A1 Opex
- Total Taxonomy Eligible but Not Aligned A2 Opex
Have Antibiotice's increased its spending in sustainable activities over time?
Since 2022, Antibiotice's taxonomy-aligned operating expenditure (OPEX) decreased by 100%, indicating a long-term decline in sustainability-related operational spending, which may reflect shifting priorities or reduced emphasis on green initiatives. a c
Compared to the previous year (2023), Antibiotice's taxonomy-aligned OPEX decreased by 100%, suggesting that Antibiotice may have reduced spending on environmentally sustainable activities, adjusted its operational priorities, or decreased the scope of its taxonomy-related disclosures. a b